Table 5.

Changes in percentage blasts in bone marrow

Bone Marrow Blasts	Tosedostat 120 mg	Tosedostat 240 mg→120 mg	Overall
Baseline, median (IQR), %	32 (16.5, 55)	35 (20. 70)	33 (18, 60)
Month 1 Bone Marrow	n=20	n=20	n=40
Median change (IQR), %	11 (−30, 170)	14 (−12, 132)	11 (−18, 165)
Patients with 50% reduction, n, %	3 (15%)	3 (15%)	6 (15%)
Patients reaching 25% blasts, n	4	4	8
Patients reaching 5% blasts, n	2	1	3
Month 2 Bone Marrow	n=22	n=16	n=38
Median change (IQR), %	20 (−41, 44)	−15 (−68, 94)	−3 (−65, 71)
Patients with 50% reduction, n, %	4 (18%)	7 (44%)	11 (29%)
Patients reaching 25% blasts, n	7	8	15
Patients reaching 5% blasts, n	1	2	3
Month 3 Bone Marrow	n=13	n=10	n=23
Median change (IQR), %	17 (−70, 46)	−40 (−85, −5)	(−17 (−85, 44)
Patients with 50% reduction, n, %	4 (31%)	5 (50%)	9 (39%)
Patients reaching 25% blasts, n	5	5	10
Patients reaching 5% blasts, n	3	2	5
Month 6 Bone Marrow	n=5	n=5	n=10
Median change (IQR), %	87.5 (−9, 149)	−89 (−97, −23)	−16 (−93, 88)
Patients with 50% reduction, n, %	1 (20%)	3 (60%)	4 (40%)
Patients reaching 25% blasts, n	1	4	5
Patients reaching 5% blasts, n	1	3	4

Changes in percentage blasts from baseline include reductions (−) and increases (+)

Patients reaching 25% or 5% includes any patient who achieved a post baseline bone marrow blast percentage of 25 or 5% following a baseline blast percentage of any value higher than these thresholds